Q3 sales jump 80% confirms Amtagvi ramp but margin and cash burn still unresolved

What happened

Iovance's Q3 earnings call confirmed that Amtagvi adoption continued to accelerate, with sales jumping 80% year-over-year and management reaffirming the 2026 revenue outlook. This aligns with the DeepValue master report's base case that 2H26 revenue would track above a $350 million annualized run-rate, but the report also stressed that gross margin had to improve from 1Q26's 41% to validate scale economics. The earnings-call commentary mentions improving margins, yet without specific quarterly gross margin or operating cash flow figures, the magnitude of that improvement cannot be verified against the report's threshold of 45%+. Meanwhile, the master report's other unresolved concerns—the FDA untitled letter on promotional claims, withdrawn UK/EU filings, and >$70 million quarterly cash burn—were not addressed in the news summary. Therefore, while the commercial trajectory appears positive, this update provides only partial confirmation of the thesis and does not yet resolve the key execution risks that justified a WAIT rating.

Implication

Investors should treat the Q3 revenue growth as supportive evidence that Amtagvi's treatment-center network is converting referrals into infusions, a key pillar of the bull case. However, the lack of specific margin improvement in the news summary means the operating leverage story remains unproven, and the stock may have already priced in the growth given the master report's trim level of $5.20. The reaffirmed 2026 outlook suggests management sees no deviation from its target, but the company still faces cash burn that could require additional equity if margins do not inflect sufficiently. Watch for the official 10-Q filing for Q3, which should disclose gross margin, inventory levels, and any updates on UK/EU resubmissions, to confirm whether the improvements are real and sustainable. Until those details are available, the WAIT rating remains appropriate, with attractive entry near $3.60 and trim above $5.20 as per the master report.

Thesis delta

The Q3 revenue jump and reaffirmed outlook slightly increase the probability of the base case scenario, but do not yet shift the thesis from WAIT to BUY. The master report's requirement for gross margin above 45% and sustained revenue growth in 3Q26 appears partially met on revenue, but margin confirmation is still lacking. Therefore, the thesis remains essentially unchanged, with only modestly increased confidence in commercial execution.